A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Journal of Carcinogenesis & Mutagenesis
doi 10.4172/2157-2518.s9-006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer

British Journal of Surgery
Surgery
2018English

A Phase I Study of Neoadjuvant Chemotherapy With Gemcitabine Plus Oral S-1 for Resectable Pancreatic Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine
2020English

Preoperative Nomogram to Predict Survival for Patients With Resectable and Borderline Resectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2017English

Folfirinox Neoadjuvant Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer - A Retrospective Study

International Journal of Contemporary Medical Research [IJCMR]
2019English

Sustained CA19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival

Oncologist
Cancer ResearchMedicineOncology
2020English

Erratum To: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival

Annals of Surgical Oncology
OncologySurgery
2014English

Neoadjuvant FOLFIRINOX for Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

Oncologist
Cancer ResearchMedicineOncology
2019English

A Pilot Phase II Study of Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Resectable Colon Cancer

Chinese Journal of Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy